tiprankstipranks
pc:sta71

Star Therapeutics

Star Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel antibodies for the treatment of bleeding disorders and other diseases. Its lead program, VGA039, is an innovative antibody targeting Protein S to restore blood clotting balance, currently undergoing a pivotal Phase 3 trial for von Willebrand Disease.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$125M
Total Amount Raised$125M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$125M
Latest Funding Amount$125M
Latest Funding RoundSeries D
Latest Funding RoundSeries D
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 08, 2025
Series D
$125.00M

Investors

Related News and Analysis